Eton Pharmaceuticals, Inc. (ETON): Shareholders' Equity
$26.15M
As of 2025-12-31
$46.59M
As of 2026-06-30
+26.0%
3-year compound annual growth
+10.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $26.15M | +7.1% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $24.43M | +57.8% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $15.48M | +18.3% | 2026-03-19, Balance as of period end |
| 2022-12-31 | $13.08M | -25.8% | 2025-03-18, Balance as of period end |
| 2021-12-31 | $17.63M | +12.6% | 2024-03-14, Balance as of period end |
| 2020-12-31 | $15.66M | +48.5% | 2023-03-16, Balance as of period end |
| 2019-12-31 | $10.55M | -59.9% | 2022-03-16, Balance as of period end |
| 2018-12-31 | $26.30M | n/m | 2021-03-16, Balance as of period end |
| 2017-12-31 | -$6.87M | n/a | 2020-03-05, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $26.15M | +7.1% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | -$185.83M | n/m |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $213.99M | -11.2% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $99.01M | n/m |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $538.75M | +2.2% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $114.26M | -55.5% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $966.90M | -8.4% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $424.29M | -10.1% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$659.62M | n/m |
Compare ETON, ADCT, ARCT, CTMX side by side · Screen every company in Pharmaceutical Preparations ↗